首页 | 本学科首页   官方微博 | 高级检索  
检索        

FGFR4蛋白表达与胃癌临床病理特征和预后的关系
引用本文:陈昊,;沈艳莹,;刘佳骅,;张子臻,;沈丹平,;倪醒之.FGFR4蛋白表达与胃癌临床病理特征和预后的关系[J].胃肠病学,2014(6):345-349.
作者姓名:陈昊  ;沈艳莹  ;刘佳骅  ;张子臻  ;沈丹平  ;倪醒之
作者单位:[1] 上海交通大学医学院附属仁济医院普外科, 200127; [2] 上海交通大学医学院附属仁济医院病理科, 200127
摘    要:背景:许多肿瘤组织中成纤维细胞生长因子受体4(FGFR4)蛋白高表达,且与患者的预后相关,然而关于FGFR4在胃癌中的表达及其作用的研究相对较少。目的:研究FGFR4在胃癌中的表达及其与胃癌临床病理特征和预后的关系。方法:应用免疫组化法检测182例胃癌组织中FGFR4蛋白表达情况,并分析其与不同胃癌临床病理特征的关系,采用Kaplan-Meier生存曲线分析FGFR4蛋白表达与预后的关系。结果:在182例胃癌组织标本中,81例(44.5%)FGFR4蛋白表达阳性,FGFR4蛋白表达与性别、年龄、肿瘤部位、分化程度、TNM分期、神经侵犯、血管侵犯均无关。FGFR4阳性与阴性者的总体5年生存率无明显差异,但在高分化、T1+T2期或伴有远处转移的胃癌中,FGFR4阳性者的预后明显差于FGFR4阴性者(5年生存率:47.0%对62.1%,P=0.036 8;5年生存率:54.5%对78.6%,P=0.041 3;中位生存期:5个月对15个月,P=0.040 5)。结论:FGFR4阳性表达尚不能作为独立指标判断胃癌预后,但在高分化胃癌、T1+T2期胃癌或伴有远处转移的胃癌中,FGFR4阳性表达可能是影响预后的危险因素。

关 键 词:胃肿瘤  受体  成纤维细胞生长因子  4型  免疫组织化学  预后

Correlation of FGFR4 Protein Expression with Clinicopathological Characteristics and Prognosis in Gastric Cancer
Institution:CHEN Hao, SHEN Yanying, LIU fiahu, ZHANG Zizhen, SHEN Danping, NI Xingzhi.( 1 Department of General Surgery, 2 Department of Pathology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai (200127))
Abstract:Fibroblast growth factor receptor 4 (FGFR4) is overexpressed and associated with prognosis in many cancers. However, studies on expression and role of FGFR4 in gastric cancer are rare. Aims: To study the FGFR4 protein expression in gastric cancer and its association with clinicopathological characteristics and prognosis. Methods: FGFR4 protein expression in 182 gastric cancer patients was examined by immunohistochemistry, and correlation of FGFR4 positivity rate with different clinicopathological characteristics was analyzed~ The correlation between expression of FGFR4 and prognosis was analyzed by Kaplan-Meier method. Results: FGFR4 expression was positive in 81 (41.5%) gastric cancer patients. The positivity rate of FGFR4 protein was not correlated with gender, age, tumor location, differentiation, TNM stage, nerve invasion and blood vessel invasion. No significant difference in overall 5-year survival rate was found between FGFR4 positive and negative groups. However, in gastric cancer patients with well-differentiation, T1 + T2 stage or distant metastasis, the prognosis in FGFR4 positive group was worse than that in FGFR4 negative group (5-year survival rate: 47.0% vs. 62. 1%, P =0. 036 8; 5-year survival rate: 54.5% vs. 78.6%, P =0.041 3; median survival: 5 months vs. 15 months, P =0.040 5). Conclusions: The FGFR4 expression is not an independent risk factor for gastric cancer, but it may be a risk factor for the prognosis of gastric cancer patients with well-differentiation, T1 + T2 stage or distant metastasis.
Keywords:Stomach Neoplasms  Receptor  Fibroblast Growth Factor  Type 4  Immunohistochemistry  Prognosis
本文献已被 CNKI 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号